Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2307 SAD Study in Healthy Japanese Subjects
NCT02289599Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2014
- Primary completion
- Feb 2015
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2307 in Alzheimer's disease (AD) (8 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Number of adverse events/serious adverse events up to 30 days, Plasma pharmacokinetics (PK) of E2307: Cmax up to 12 days and 9 more. Started Nov 2014; status: completed.
02
Drugs
E2307
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02289599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289599.